Pfizer Stops Developing Hepatitis C Drug
"BY PETER LOFTUS
Pfizer Inc. has stopped development of an experimental hepatitis C drug, bowing out of a hotly contested industry race to introduce the next generation of treatments for the infectious liver disease.
The New York-based drug giant decided to discontinue development of PF-00868554, also known as filibuvir, following a strategic review, said spokeswoman Victoria Davis. She said the decision wasn't related to any safety issues.
The drug was in midstage clinical testing, further behind in development than potential new hepatitis C treatments from ..."
Such facts make Vertex more valuable.
Sentiment: Strong Buy